Korean J Hepatobiliary Pancreat Surg.  2013 Feb;17(1):8-13. 10.14701/kjhbps.2013.17.1.8.

Pancreas club international joint symposium on pancreatic cancer 2012, Kyoto: down staging chemo+/-radiotherapy for borderline resectable pancreatic cancer

  • 1Department of Surgery, Yonsei University College of Medicine, Seoul, Korea. wjlee@yuhs.ac


This manuscript summarized one section out of the international symposium, Pancreatic Cancer 2012, which was held last October 4th through 6th in Kyoto (Japan) under the theme, "We are the Team: Opening the Door to the Next Step for Pancreatic Cancer Therapy." Borderline resectable pancreatic cancer (BRPC) is a specific clinical presentation with features in between those of resectable and locally advanced pancreatic cancers. The classification of pancreatic cancer is an important issue given that a cancer may look resectable but be high-risk for R1 or R2 resection. Considering that margin-negative resection is a fundamental requirement for curing pancreatic cancer, this issue is one of the most interesting to pancreatic surgeons. At Pancreatic Cancer 2012 in Kyoto, BRPC was also discussed at the Pancreatic Club International Joint Symposium. In this manuscript, the contents of the presented topics are briefly summarized to facilitate understanding of recent issues in managing BRPC.


Pancreatic cancer; Respectability; Chemoradiation therapy

MeSH Terms

Pancreatic Neoplasms


1. Ouaissi M, Hubert C, Verhelst R, et al. Multidisciplary HPB Group of Center of Cancer. Vascular reconstruction during pancreatoduodenectomy for ductal adenocarcinoma of the pancreas improves resectability but does not achieve cure. World J Surg. 2010; 34:2648–2661. PMID: 20607257.
2. Sho M, Akahori T, Tanaka T, et al. Pathological and clinical impact of neoadjuvant chemoradiotherapy using full-dose gemcitabine and concurrent radiation for resectable pancreatic cancer. J Hepatobiliary Pancreat Sci. 2013; 20:197–205. PMID: 22766692.
3. Kang CM, Chung YE, Park JY, et al. Potential contribution of preoperative neoadjuvant concurrent chemoradiation therapy on margin-negative resection in borderline resectable pancreatic cancer. J Gastrointest Surg. 2012; 16:509–517. PMID: 22183861.
4. Satoi S, Toyokawa H, Yanagimoto H, et al. Neo-adjuvant chemoradiation therapy using S-1 followed by surgical resection in patients with pancreatic cancer. J Gastrointest Surg. 2012; 16:784–792. PMID: 22160780.
5. Morganti AG, Massaccesi M, La Torre G, et al. A systematic review of resectability and survival after concurrent chemoradiation in primarily unresectable pancreatic cancer. Ann Surg Oncol. 2010; 17:194–205. PMID: 19856029.
6. Talamonti MS, Small W Jr, Mulcahy MF, et al. A multi-institutional phase II trial of preoperative full-dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinoma. Ann Surg Oncol. 2006; 13:150–158. PMID: 16418882.
7. Hoffman JP, Lipsitz S, Pisansky T, et al. Phase II trial of preoperative radiation therapy and chemotherapy for patients with localized, resectable adenocarcinoma of the pancreas: an Eastern Cooperative Oncology Group Study. J Clin Oncol. 1998; 16:317–323. PMID: 9440759.
8. Massucco P, Capussotti L, Magnino A, et al. Pancreatic resections after chemoradiotherapy for locally advanced ductal adenocarcinoma: analysis of perioperative outcome and survival. Ann Surg Oncol. 2006; 13:1201–1208. PMID: 16955382.
9. Breslin TM, Hess KR, Harbison DB, et al. Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration. Ann Surg Oncol. 2001; 8:123–132. PMID: 11258776.
10. Wang F, Kumar P. The role of radiotherapy in management of pancreatic cancer. J Gastrointest Oncol. 2011; 2:157–167. PMID: 22811846.
11. Callery MP, Chang KJ, Fishman EK, et al. Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement. Ann Surg Oncol. 2009; 16:1727–1733. PMID: 19396496.
12. NPCPP. Adenocarcinoma. NCCN Clinical Practice Guidelines in Oncology; vesrion 2. 2011. 2011. Forth Washington, PA: National Comprehensive Care Network Inc.
13. Lu DS, Reber HA, Krasny RM, et al. Local staging of pancreatic cancer: criteria for unresectability of major vessels as revealed by pancreatic-phase, thin-section helical CT. AJR Am J Roentgenol. 1997; 168:1439–1443. PMID: 9168704.
14. Shrikhande SV, Arya S, Barreto SG, et al. Borderline resectable pancreatic tumors: is there a need for further refinement of this stage? Hepatobiliary Pancreat Dis Int. 2011; 10:319–324. PMID: 21669578.
15. Donahue TR, Isacoff WH, Hines OJ, et al. Downstaging chemotherapy and alteration in the classic computed tomography/magnetic resonance imaging signs of vascular involvement in patients with pancreaticobiliary malignant tumors: influence on patient selection for surgery. Arch Surg. 2011; 146:836–843. PMID: 21768431.
16. Chun YS, Cooper HS, Cohen SJ, et al. Significance of pathologic response to preoperative therapy in pancreatic cancer. Ann Surg Oncol. 2011; 18:3601–3607. PMID: 21947697.
17. Katz MH, Varadhachary GR, Fleming JB, et al. Serum CA 19-9 as a marker of resectability and survival in patients with potentially resectable pancreatic cancer treated with neoadjuvant chemoradiation. Ann Surg Oncol. 2010; 17:1794–1801. PMID: 20162463.
18. NCCN Comprehensive Cancer Network (NCCN). NCCN updates pancreatic adenocarcinoma guidelines. Available at; http://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf.
19. Murata Y, Hamada T, Kishiwada M, et al. Human equilibrative nucleoside transporter 1 expression is a strong independent prognostic factor in UICC T3-T4 pancreatic cancer patients treated with preoperative gemcitabine-based chemoradiotherapy. J Hepatobiliary Pancreat Sci. 2012; 19:413–425. PMID: 21898089.
20. Farrell JJ, Elsaleh H, Garcia M, et al. Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. Gastroenterology. 2009; 136:187–195. PMID: 18992248.
21. Robins MJ, Peng Y, Damaraju VL, et al. Improved syntheses of 5'-S-(2-aminoethyl)-6-N-(4-nitrobenzyl)-5'-thioadenosine (SAENTA), analogues, and fluorescent probe conjugates: analysis of cell-surface human equilibrative nucleoside transporter 1 (hENT1) levels for prediction of the antitumor efficacy of gemcitabine. J Med Chem. 2010; 53:6040–6053. PMID: 20718495.
22. Ishikawa O, Ohhigashi H, Teshima T, et al. Clinical and histopathological appraisal of preoperative irradiation for adenocarcinoma of the pancreatoduodenal region. J Surg Oncol. 1989; 40:143–151. PMID: 2918720.
23. Evans DB, Rich TA, Byrd DR, et al. Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg. 1992; 127:1335–1339. PMID: 1359851.
24. White RR, Xie HB, Gottfried MR, et al. Significance of histological response to preoperative chemoradiotherapy for pancreatic cancer. Ann Surg Oncol. 2005; 12:214–221. PMID: 15827813.
25. Hartman DJ, Krasinskas AM. Assessing treatment effect in pancreatic cancer. Arch Pathol Lab Med. 2012; 136:100–109. PMID: 22208494.
Full Text Links
export Copy
  • Twitter
  • Facebook
Similar articles
Copyright © 2022 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr